Tasigna Has Rapid Response

[Guest guest]

" New data show that at 24 months, patients in the chronic phase of Philadelphia

chromosome positive (Ph+) chronic myeloid leukaemia (CML) who are intolerant or

resistant to current first-line therapy (Glivec) experienced a rapid response

and significant reduction in leukaemia burden when treated with 400mg Tasigna

twice-daily1. Furthermore, the research shows that the majority of patients in

both the chronic and accelerated phases of the disease are still alive at 2

years when treated with Tasigna1,2.

" The results, presented at the 14th Congress of the European Haematology

Association (EHA) in Berlin, Germany are based on a phase II single treatment

study of 321 chronic phase, adult patients with Ph+ CML and 137 accelerated

phase patients with Ph+ CML who were intolerant or resistant to the current

gold-standard treatment Glivec1,2. The results substantiate data presented at

the American Society of Haematology meeting in San Francisco last year.

" The data show that response times were rapid with 94% of all patients reaching

complete haematologic response (CHR) (meaning blood counts returned to normal)

at a median of one month following initiation of therapy1. In patients that had

not previously reached haematological response, 75% reached haematological

response1. Complete cytogenic response (CCyR), meaning no Ph chromosomes could

be detected in the bone marrow was reached by 44% of patients at a median of 3.3

months following initiation of therapy1. "

Source: European Haematology Association (View drug information on Tasigna.)

http://www.medicalnewstoday.com/articles/155782.php

FYI,

Lottie Duthu